Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Sumitomo Dainippon to Solely Promote Novartis Diabetes Meds from January
November 20, 2019
- Mitsubishi Chemical to Fully Own Mitsubishi Tanabe to Solidify Healthcare Platform
November 19, 2019
- Fujifilm Kicks Off US PI Study for Topotecan Liposome Drug
November 19, 2019
- Takeda Eyes 12 NME Approvals over Next 5 Years
November 19, 2019
- Shionogi Wins US Approval for Antibiotic Fetroja
November 18, 2019
- Stemirac’s 44 Million Yen Sales Within Expectations, Says Nipro President
November 15, 2019
- Big 3 Generic Firms Enjoy 7.8% Growth, AG Makers Triumph: Jiho Tally
November 15, 2019
- Fujifilm to Make 13 Billion Yen Investment in Gene Therapy Facilities in US
November 15, 2019
- Big 4 Japan Wholesalers Eke Out 1% Operating Margins: Jiho Tally
November 14, 2019
- Kyowa Pharma Set to Accelerate Beyond-the-Pill Growth after Lupin’s Divestment Deal: Chief
November 14, 2019
- Otsuka/Avanir to Carry On Development of Alzheimer’s Agitation Drug
November 14, 2019
- Otsuka’s Pharma Biz Zooms 14.0% in January-September on 4 Global Brands
November 14, 2019
- Ajinomoto, Kanagawa Cancer Center Team Up for Research for Next-Gen Treatment/Diagnosis Technology
November 14, 2019
- Rohto to Snap Up Nitten Pharmaceutical to Tap Into Ethical Eye Drop Arena
November 14, 2019
- Half of R&D Money Going towards Cancer Meds, Exec Says Oncology Will Be GSK’s “Next Respiratory”
November 13, 2019
- AstraZeneca, Omron Healthcare Pair Up to Develop Disease Management Solutions
November 13, 2019
- Ono, BMS File Opdivo/Yervoy Combo for MSI-H Colorectal Cancer in Japan
November 13, 2019
- Sandoz to Buy Aspen’s Japan Biz for Up to 400 Million Euros
November 12, 2019
- Mitsubishi Tanabe’s HIF-PH Inhibitor Shows Non-Inferiority to ESA in Japan PIII Study
November 12, 2019
- Japan Ethical Drug Sales Spike 19.7% in September: Crecon
November 12, 2019
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…